Currently, Small cell lung cancer is still treated with the conventional chemotherapy agents namely platinum-based chemotherapies such as carboplatin and etoposide (CE), or Cisplatin Irinotecan (CI), American Cancer Society, 2019 https://www.cancer.org/cancer/small-cell-lung-cancer/treating/chemotherapy.htm l
Given the fact that, these chemotherapies have a lot of toxicities such as nausea, vomiting, weight loss, peripheral neuropathies and kidney toxicities, it was logic to think about other non-chemotherapy related means of treatment.
Recent research on the small cell lung cancer was initiated by Tay et al (2019) https://www.lungcancerjournal.info/article/S0169-5002(19)30625-7/fulltext looking for alternative treatments that target small cell lung cancer without the high toxicity profile of the standard chemotherapies. These new therapies are known as immune therapy. These immune therapies target checkpoints and are defined as a checkpoints blockers. The researchers in this study performed a full review of the role of these immune therapies (namely, Anti PD(L)1 and CTLA 4) in Small Cell Lung Cancer. They reviewed many Phase I, II and III clinical trials on using these immune therapies in Small Cell Lung Cancer. Interestingly, they concluded that these immune therapies can be active agents in managing and treating patients with the Small Cell Lung Cancer. The recommendation from this study was to design prospective randomized trials aiming at comparing these immune therapies with the standard chemotherapy for the Small Cell Lung Cancer.
If you have any question, don’t hesitate to contact us at this link